NMRD | Nemaura Medical Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0002 - 0.0002
52 Week Range	0.0001 - 0.2537
Beta	-0.09
Implied Volatility	501.87%
IV Rank	6.84%
Day's Volume	325
Average Volume	5,832
Shares Outstanding	40,351,700
Market Cap	8,070
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2018-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-0.39
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	36
Country	USA
Website	NMRD

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NMRD's peers: MODD, BMRA, BSGM, CODX, NMTC, NXL

*Chart delayed

Analyzing fundamentals for NMRD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NMRD Fundamentals page.

Watching at NMRD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NMRD Technicals page.